Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones [Seeking Alpha]
Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026